Advertisement
Canada markets closed
  • S&P/TSX

    21,642.87
    -97.33 (-0.45%)
     
  • S&P 500

    5,051.41
    -10.41 (-0.21%)
     
  • DOW

    37,798.97
    +63.86 (+0.17%)
     
  • CAD/USD

    0.7236
    +0.0003 (+0.04%)
     
  • CRUDE OIL

    85.37
    +0.01 (+0.01%)
     
  • Bitcoin CAD

    88,057.73
    +396.73 (+0.45%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,399.70
    -8.10 (-0.34%)
     
  • RUSSELL 2000

    1,967.48
    -8.23 (-0.42%)
     
  • 10-Yr Bond

    4.6590
    +0.0310 (+0.67%)
     
  • NASDAQ futures

    17,932.50
    +51.25 (+0.29%)
     
  • VOLATILITY

    18.40
    -0.83 (-4.32%)
     
  • FTSE

    7,820.36
    -145.17 (-1.82%)
     
  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     
  • CAD/EUR

    0.6811
    +0.0003 (+0.04%)
     

Stocks - Apple, Amazon Fall in Pre-market; Barnes & Noble Surges

Stocks to watch out for on Thursday.
Stocks to watch out for on Thursday.

Investing.com - Stocks in focus in pre-market trade Thursday:

· Barnes & Noble (NYSE:BKS) stock jumped 21.25% as of 8:20 AM ET (12:20 GMT) after the struggling bookstore chain announced it was exploring a takeover.

· Tilray (NASDAQ:TLRY) stock slumped 3.72% after the company announced it was offering $400 million worth of convertible senior notes to be used for working capital, acquisitions and to repay a $9.1 million mortgage on a production facility in British Columbia.

· Apple (NASDAQ:AAPL) and Amazon.com (NASDAQ:AMZN) stocks fell after a Bloomberg report that China used small chips to initiate a supply chain attack. Both companies refuted the claims. Apple stock fell 0.73%, while Amazon stock decreased 0.47%. Amazon also announced that warehouse workers would no longer receive stock or collect bonuses, just days after announcing it would boost the minimum wage to $15 an hour.

ADVERTISEMENT

· Constellation Brands (NYSE:STZ) gained 4% after its earnings came in higher than expected.

· Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock surged 18.21% after the company said it entered a $3.7 billion deal with Janssen Pharmaceuticals, owned by Johnson & Johnson (NYSE:JNJ), to develop a treatment for chronic hepatitis B.

Related Articles

High stakes: Risk in Nasdaq's Nordic power market boomed before default

Dollar and global bonds track surge in Treasury yields, stocks sag

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion